Quentin Monchicourt’s Post

Join us in celebrating Dr. Kevin Rosi as he approaches his nine-year anniversary with Mindful Health Solutions! Dr. Rosi has played a pivotal role in the evolution of our interventional treatments, particularly in the advancement and application of Transcranial Magnetic Stimulation (TMS). Here's his reflection on the journey and the incredible impact TMS has had on the lives of treatment-resistant patients: "As I approach my nine-year anniversary with Mindful Health Solutions, I have been reflecting upon the evolution of our interventional treatments and how they improve the lives of treatment-resistant patients. When I joined MHS in 2015, I was immediately educated and trained in Transcranial Magnetic Stimulation (TMS), having only a cursory understanding of the treatment. In my first year of treating patients using TMS, I quickly understood how safe and effective the treatment was, even in the most chronically depressed patients. I have seen hundreds of depressed patients improve from TMS and feel grateful that I can offer patients hope when other treatments have failed. In the past five years, the field of TMS has advanced beyond depression and received FDA clearance for other conditions, including Obsessive Compulsive Disorder and smoking cessation. Research also strongly supports prescribing TMS for Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, as well as conditions outside of Psychiatry, specifically Neuropathic Pain. With the support of MHS leadership, myself and Dr. Ben Williamson have developed our Pain Protocol, employing TMS to treat Neuropathic Pain based on the latest cutting-edge research. It is extremely rewarding to see the improvement in both mental and physical health symptoms with TMS, and I am looking forward to future advances in the field of Interventional Psychiatry. This is truly an exciting time to be working in mental health. The annual Clinical TMS SocietyMeeting in London last month brought together leading clinicians and researchers in the field, offering the opportunity to enhance our knowledge and practice of TMS. Nine years ago, I had no idea I was entering into a field that would grow into what we now call Interventional Psychiatry, but I am forever grateful. I have witnessed TMS change the lives of so many patients in need, and I realize how offering this treatment has changed my life as well." #TMS #InnovativePsychiatry #MindfulHealthSolutions

🎥 New Special Report! 🎥 We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry

https://lnkd.in/g5qk52NU                                                                    Article title: Comparison of two questionnaires (PDQ-39 and SEIQoL) for assessment of the quality of life in idiopathic Parkinson’s disease   Author(s): Lena Waldvogel; Ketevan Toloraia; Peter Fuhr; Ute Gschwandtner* Journal: Annals of Psychiatry and Treatment   Journal ISSN: 2640-8031 Abstract: Parkinson’s disease is a neurodegenerative disease of the central nervous system that begins insidiously and progresses over time with a loss of nerve cells in certain brain regions. People with chronic diseases often experience a change in their quality of life. For patients, relatives, and the whole community, a reduced quality of life can pose a significant burden. Therefore, it is imperative to reduce socioeconomic costs to preserve high health quality in patients with neurodegenerative disorders. Parkinson’s disease can cause people to have difficulty performing daily activities such as working or shopping. It is not uncommon for social interaction to be impaired, as patients sometimes struggle to participate in social life due to their symptomatology. The quality of life of Parkinson’s disease patients can be measured in different ways. A distinction can be made between Health-related Quality of Life and Individualised Quality of Life. Several questionnaires and screening tools are investigating the Quality of Life in patients with Parkinson’s disease. However, their validity and practicability are often not extensively analyzed. #ParkinsonsDisease #PDQ39 #SEIQoL #QualityOfLife #Neurodegeneration #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia

Clinical trial compared Behavioral Activation (BA) psychotherapy with #antidepressants #medicationmanagement in patients with #heartfailure and #depression. 50% of individuals with heart failure experience depressive symptoms. There is increased medication burden with both comorbidities. Due to concerns about the effectiveness of #psychotherapy and the adverse effects of antidepressants, clinicians and patients lack evidence on which intervention to use. Unlike complex CBT, BA therapy focuses mostly on improvement of patient mood, sense of control, and activity level through increased engagement in pleasurable and rewarding tasks, has comparable efficacy to CBT but "more feasible in patients with HF”. Study results: - BA was comparable to antidepressant medication in relieving symptoms of depression. - BA demonstrated slightly more improvement in physical health-related quality of life (HRQOL), and had fewer emergency department (ED) visits and days of hospitalization. Researchers concluded: BA stimulated patient activation, increased enjoyable physical activity, motivation, self care, and absence of antidepressant medication burden might be contributing factors. #cardiology #psychotherapy #psychiatry #pharmacy #pharmacists #polypharmacy

Collaboration Announcement We are thrilled to announce a strategic collaboration between HMNC Brain Health and Spruce Biosciences to advance the treatment of Major Depressive Disorder (MDD). https://lnkd.in/gP-mnv6w This partnership aims to combine Spruce's investigational product candidate, tildacerfont, with HMNC's proprietary companion diagnostic, Cortibon Genetic Selection Tool.   🔬 Key Highlights:   Combination Therapy: tildacerfont, a second-generation CRF1 receptor antagonist, paired with HMNC’s Cortibon Genetic Selection Tool to identify MDD patients responsive to the targeted treatment. Phase 2 Study: HMNC will initiate a Phase 2 proof-of-concept study later this year.   This collaboration shows our joint commitment to precision psychiatry, addressing patient heterogeneity, and enhancing treatment efficacy through personalized medicine.   We will share more updates as we embark on this journey towards better mental health solutions. #HMNCBrainHealth #personalizedmedicine #depression #depressiontreatment #Collaboration #Innovation

🌟 Tap into a New Possibility for OCD Treatment with NeuroStar! 🌟 As a psychiatrist, I am always on the lookout for innovative treatments that can provide relief to my patients. I'm excited to share Neuronetics, Inc. NeuroStar's Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD). 📈 Why NeuroStar TMS? FDA-cleared Not medicine Not shock therapy Non-invasive Safe and effective NeuroStar TMS is an advanced way to treat OCD, offering a non-invasive, drug-free option for those struggling with this challenging condition. It's shown significant improvement in OCD symptoms through focused magnetic pulses targeting areas in the brain involved in OCD. 🧠 How It Works: NeuroStar TMS uses targeted magnetic pulses to stimulate areas of the brain associated with OCD. This treatment is done in an outpatient setting, making it a convenient option for many. If you or someone you know is battling OCD, consider exploring this revolutionary treatment. Let's break the stigma around mental health and embrace innovative solutions! 📞 Contact us at getbetter@gentms.com or call 571.732.3302 to learn more and see if NeuroStar TMS is right for you. #MentalHealth #OCD #NeuroStar #TMSTherapy #Psychiatry

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

In the ever-dynamic field of psychiatry, understanding the interplay of neurobiology, psychosocial factors, and environmental influences continues to reshape our approaches to diagnosis and treatment. As mental health clinicians, we are increasingly leveraging advancements in neuroimaging, psychopharmacology, and genetic predisposition analysis to deliver tailored care that aligns with each patient’s biopsychosocial matrix. One area of particular interest is the ongoing exploration of neurotransmitter dysregulation in mood disorders. For example, research into the glutamatergic system and its role in treatment-resistant depression has led to a surge in the utilization of NMDA receptor antagonists like esketamine, offering renewed hope for individuals unresponsive to traditional serotonergic interventions. Simultaneously, the integration of digital therapeutics and telepsychiatry platforms has expanded access to care while enhancing adherence through evidence-based behavioral interventions. The advent of AI-driven diagnostic tools further supports clinicians by identifying subtle patterns in symptomatology, bridging gaps in early detection and intervention. As we navigate these advancements, it is crucial to maintain a patient-centered framework, addressing not only the psychopathological phenomena but also the stigmatization that often accompanies psychiatric diagnoses. By fostering therapeutic alliances and promoting psychoeducation, we empower individuals to engage actively in their treatment journey, bolstering long-term outcomes. The intersection of psychiatry and innovation promises an exciting future, but it also challenges us to remain adaptable, empathetic, and rooted in evidence-based practices. For colleagues in the field: what trends or innovations do you see transforming psychiatric care in the coming years? Let’s advance this dialogue to better serve our patients and the mental health community. #Psychiatry #MentalHealth #Neurotransmitters #AIpsych

"The conference will highlight a paradigm shift in medicine and the newfound recognition of immune dysregulation in some patients with OCD, psychosis, depression, anxiety, schizophrenia, and mental health conditions previously viewed solely through the lens of psychiatry. Attendees can expect a fresh perspective on mental health, with presentations on the role of neuroinflammation in some psychiatric deteriorations, the impact of immune dysregulation on mental health, and therapeutic strategies that leverage immunomodulation to address symptoms that have historically been treated primarily with psychotropics." #cme #cmecredits https://lnkd.in/e2zbZeWK